Literature DB >> 19843400

Allergic rhinitis, histamine, and otitis media.

Amanda R Skoner1, Kelleen R Skoner, David P Skoner.   

Abstract

Otitis media (OM) is a common and costly medical condition, especially in children. Most episodes of OM are associated with an upper respiratory viral infection and are short-lived and self-limiting with or without medical treatment. However, chronic OM with effusion (OME) has significant sequelae, is refractory to most medical treatments, and frequently requires surgical intervention. The pathophysiology of OME is complex and involves both eustachian tube (ET) dysfunction and middle ear pressure dysregulation. OM likely results from an increase in blood flow to and, thus, gas loss from the middle ear, in combination with a dysfunctional ET that can not resupply that gas. These processes could be induced by viral and/or allergen-driven inflammation. A large body of epidemiologic and mechanistic evidence supports a role for allergic rhinitis as a risk for OM. Indeed, evidence also supports a role for histamine in both conditions. However, not all such evidence is supportive of this relationship and a causal relationship between the two conditions has not been definitively proven. Moreover, therapeutic trials using common allergy therapies have either not been conducted or showed no benefit in OM. This prompted the 2004 clinical practice guidelines on OM to conclude that no recommendations could be made for "... allergy management as a treatment for OME based on insufficient evidence of therapeutic efficacy or a causal relationship between allergy and OME." Nonetheless, given the strong likelihood of allergy as a risk factor for OM, allergic rhinitis patients should be evaluated for OM and patients with OME should be considered for an allergy evaluation. If significant allergic rhinitis is diagnosed in a patient with OME, it should be treated aggressively (as in any case of moderate to severe allergic rhinitis) until further studies are conducted. No definitive conclusions about a role for food allergy in causing or treating OM can be made. Clearly, more studies are needed to examine the relationship between these two important conditions.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19843400     DOI: 10.2500/aap.2009.30.3272

Source DB:  PubMed          Journal:  Allergy Asthma Proc        ISSN: 1088-5412            Impact factor:   2.587


  7 in total

1.  Sinus and adenoid inflammation in children with chronic rhinosinusitis and asthma.

Authors:  Antony Anfuso; Hassan Ramadan; Andrew Terrell; Yesim Demirdag; Cheryl Walton; David P Skoner; Giovanni Piedimonte
Journal:  Ann Allergy Asthma Immunol       Date:  2015-02       Impact factor: 6.347

Review 2.  Should newborns be screened for immunodeficiency?: lessons learned from infants with recurrent otitis media.

Authors:  Yesim Yilmaz-Demirdag
Journal:  Curr Allergy Asthma Rep       Date:  2011-12       Impact factor: 4.806

3.  Nasal Allergy and Otitis Media: A real correlation?

Authors:  Desiderio Passali; Giulio C Passali; Maria Lauriello; Antonio Romano; Luisa Bellussi; Francesco M Passali
Journal:  Sultan Qaboos Univ Med J       Date:  2014-01-27

Review 4.  Interaction Between Allergy and Middle Ear Infection.

Authors:  Jeong-Hoon Oh; Woo Jin Kim
Journal:  Curr Allergy Asthma Rep       Date:  2016-09       Impact factor: 4.806

5.  Assessment of the association between atopic conditions and tympanostomy tube placement in children.

Authors:  Kara A Bjur; Rachel L Lynch; Yilma A Fenta; Kwang Ha Yoo; Robert M Jacobson; Xujian Li; Young J Juhn
Journal:  Allergy Asthma Proc       Date:  2012 May-Jun       Impact factor: 2.587

6.  Association between atopy, mastoid pneumatization and tympanometric findings.

Authors:  Mustafa Kaymakçı; Bahar Yanık; Fuat Erel; Nuray Bayar Muluk; Cemal Cingi
Journal:  Eur Arch Otorhinolaryngol       Date:  2014-03-20       Impact factor: 2.503

Review 7.  New paradigms in the pathogenesis of otitis media in children.

Authors:  James Mark Coticchia; Michael Chen; Livjot Sachdeva; Sean Mutchnick
Journal:  Front Pediatr       Date:  2013-12-23       Impact factor: 3.418

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.